Literature DB >> 23758584

Design of cell-permeable stapled peptides as HIV-1 integrase inhibitors.

Ya-Qiu Long1, Shao-Xu Huang, Zahrah Zawahir, Zhong-Liang Xu, Huiyuan Li, Tino W Sanchez, Ying Zhi, Stephanie De Houwer, Frauke Christ, Zeger Debyser, Nouri Neamati.   

Abstract

HIV-1 integrase (IN) catalyzes the integration of viral DNA into the host genome, involving several interactions with the viral and cellular proteins. We have previously identified peptide IN inhibitors derived from the α-helical regions along the dimeric interface of HIV-1 IN. Herein, we show that appropriate hydrocarbon stapling of these peptides to stabilize their helical structure remarkably improves the cell permeability, thus allowing inhibition of the HIV-1 replication in cell culture. Furthermore, the stabilized peptides inhibit the interaction of IN with the cellular cofactor LEDGF/p75. Cellular uptake of the stapled peptide was confirmed in four different cell lines using a fluorescein-labeled analogue. Given their enhanced potency and cell permeability, these stapled peptides can serve as not only lead IN inhibitors but also prototypical biochemical probes or "nanoneedles" for the elucidation of HIV-1 IN dimerization and host cofactor interactions within their native cellular environment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23758584      PMCID: PMC6188661          DOI: 10.1021/jm4006516

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  49 in total

1.  An improved synthesis of chiral alpha-(4-bromobenzyl)alanine ethyl ester and its application to the synthesis of LFA-1 antagonist BIRT-377.

Authors:  S R Kapadia; D M Spero; M Eriksson
Journal:  J Org Chem       Date:  2001-03-09       Impact factor: 4.354

Review 2.  Cyclization strategies in peptide derived drug design.

Authors:  Peng Li; Peter P Roller
Journal:  Curr Top Med Chem       Date:  2002-03       Impact factor: 3.295

3.  Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity.

Authors:  Elvire Guiot; Kevin Carayon; Olivier Delelis; Françoise Simon; Patrick Tauc; Evgenii Zubin; Marina Gottikh; Jean-François Mouscadet; Jean-Claude Brochon; Eric Deprez
Journal:  J Biol Chem       Date:  2006-06-13       Impact factor: 5.157

4.  Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.

Authors:  Hui-Yuan Li; Zahrah Zawahir; Lai-Dong Song; Ya-Qiu Long; Nouri Neamati
Journal:  J Med Chem       Date:  2006-07-27       Impact factor: 7.446

Review 5.  Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy.

Authors:  Laith Q Al-Mawsawi; Nouri Neamati
Journal:  Trends Pharmacol Sci       Date:  2007-09-21       Impact factor: 14.819

6.  Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide.

Authors:  Federico Bernal; Andrew F Tyler; Stanley J Korsmeyer; Loren D Walensky; Gregory L Verdine
Journal:  J Am Chem Soc       Date:  2007-02-07       Impact factor: 15.419

7.  Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

Authors:  Jan van Lunzen; Franco Maggiolo; José R Arribas; Aza Rakhmanova; Patrick Yeni; Benjamin Young; Jürgen K Rockstroh; Steve Almond; Ivy Song; Cindy Brothers; Sherene Min
Journal:  Lancet Infect Dis       Date:  2011-10-20       Impact factor: 25.071

8.  Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity.

Authors:  Toru Okamoto; Kerry Zobel; Anna Fedorova; Clifford Quan; Hong Yang; Wayne J Fairbrother; David C S Huang; Brian J Smith; Kurt Deshayes; Peter E Czabotar
Journal:  ACS Chem Biol       Date:  2012-12-10       Impact factor: 5.100

Review 9.  Treatment of HIV infection with once-daily regimens.

Authors:  Nitipong Permpalung; Opass Putcharoen; Anchalee Avihingsanon; Kiat Ruxrungtham
Journal:  Expert Opin Pharmacother       Date:  2012-10-08       Impact factor: 3.889

10.  Transportin-SR2 imports HIV into the nucleus.

Authors:  Frauke Christ; Wannes Thys; Jan De Rijck; Rik Gijsbers; Alberto Albanese; Daniele Arosio; Stephane Emiliani; Jean-Christophe Rain; Richard Benarous; Anna Cereseto; Zeger Debyser
Journal:  Curr Biol       Date:  2008-08-26       Impact factor: 10.834

View more
  6 in total

1.  Generation of a long-acting fusion inhibitor against HIV-1.

Authors:  Ye Guo; Pan-Pan Zhou; Sen-Yan Zhang; Xiao-Wen Fan; Yu-Wei Dou; Xuan-Ling Shi
Journal:  Medchemcomm       Date:  2018-06-06       Impact factor: 3.597

2.  Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation.

Authors:  Ewa D Micewicz; Shantanu Sharma; Alan J Waring; Hai T Luong; William H McBride; Piotr Ruchala
Journal:  Int J Pept Res Ther       Date:  2015-08-19       Impact factor: 1.931

Review 3.  Hydrocarbon-stapled peptides: principles, practice, and progress.

Authors:  Loren D Walensky; Gregory H Bird
Journal:  J Med Chem       Date:  2014-03-06       Impact factor: 7.446

4.  Z-Selective olefin metathesis on peptides: investigation of side-chain influence, preorganization, and guidelines in substrate selection.

Authors:  Shane L Mangold; Daniel J O'Leary; Robert H Grubbs
Journal:  J Am Chem Soc       Date:  2014-08-20       Impact factor: 15.419

5.  Influence of macrocyclization on allosteric, juxtamembrane-derived, stapled peptide inhibitors of the epidermal growth factor receptor (EGFR).

Authors:  Julie K-L Sinclair; Alanna Schepartz
Journal:  Org Lett       Date:  2014-09-10       Impact factor: 6.005

6.  Development and Identification of a Novel Anti-HIV-1 Peptide Derived by Modification of the N-Terminal Domain of HIV-1 Integrase.

Authors:  Marina Sala; Antonia Spensiero; Francesca Esposito; Maria C Scala; Ermelinda Vernieri; Alessia Bertamino; Michele Manfra; Alfonso Carotenuto; Paolo Grieco; Ettore Novellino; Marta Cadeddu; Enzo Tramontano; Dominique Schols; Pietro Campiglia; Isabel M Gomez-Monterrey
Journal:  Front Microbiol       Date:  2016-06-10       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.